Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5926
Hemab Therapeutics
COAG
$1.42B
| $150K | ﹤0.01% |
+4,078
| New | +$113K |
2026 Q2
0 quarters
|
|
5927
MAIA Biotechnology
MAIA
$72.9M
| $150K | ﹤0.01% |
104,017
+90,158
| +651% | +$120K |
2023 Q3
11 quarters
|
|
5928
ProShares Ultra Gold
UGL
$727M
| $149K | ﹤0.01% |
3,406
-23,194
| -87% | -$1.31M |
2013 Q3
51 quarters
|
|
5929
Fidelity Fundamental Small-Mid Cap ETF
FFSM
$1.5B
| $149K | ﹤0.01% |
3,907
+1,394
| +55% | +$49.7K |
2023 Q4
10 quarters
|
|
5930
Rare Earths Americas Inc
REA
$190M
| $149K | ﹤0.01% |
+9,768
| New | +$193K |
2026 Q2
0 quarters
|
|
5931
EA Bridgeway Blue Chip ETF
BBLU
$482M
| $149K | ﹤0.01% |
9,041
+1,001
| +12% | +$16.1K |
2022 Q4
14 quarters
|
|
5932
Innovator US Equity Buffer ETF October
BOCT
$304M
| $149K | ﹤0.01% |
2,809
| – | – |
2023 Q4
10 quarters
|
|
5933
iShares MSCI Qatar ETF
QAT
$54.5M
| $148K | ﹤0.01% |
8,234
+6,446
| +361% | +$121K |
2016 Q1
41 quarters
|
|
5934
First Trust Alerian Disruptive Technology Real Estate ETF
DTRE
$14M
| $148K | ﹤0.01% |
3,563
-670
| -16% | -$28.3K |
2013 Q2
52 quarters
|
|
5935
Tvardi Therapeutics
TVRD
$14.1M
| $148K | ﹤0.01% |
77,845
+4,951
| +7% | +$15.5K |
2014 Q1
49 quarters
|
|
5936
ProShares Ultra Bloomberg Crude Oil
UCO
$455M
| $148K | ﹤0.01% |
4,485
-16,846
| -79% | -$724K |
2013 Q4
50 quarters
|
|
5937
FT Vest US Equity Deep Buffer ETF February
DFEB
$452M
| $148K | ﹤0.01% |
2,925
-396
| -12% | -$19.7K |
2020 Q3
23 quarters
|
|
5938
Schwab Municipal Bond ETF
SCMB
$3.13B
| $148K | ﹤0.01% |
5,715
+19
| +0.3% | +$487 |
2025 Q2
4 quarters
|
|
5939
CalciMedica
CALC
$8.26M
| $148K | ﹤0.01% |
+28,649
| New | +$102K |
2026 Q2
0 quarters
|
|
5940
DELISTED
GETTY IMAGES HLDGS INC A
GETY
| $147K | ﹤0.01% |
171,176
+18,307
| +12% | +$15.8K |
2022 Q3
15 quarters
|
|
5941
Innovator US Equity Power Buffer ETF April
PAPR
$964M
| $146K | ﹤0.01% |
3,468
| – | – |
2022 Q3
15 quarters
|
|
5942
Amplify BlueStar Israel Technology ETF
ITEQ
$106M
| $146K | ﹤0.01% |
2,203
+230
| +12% | +$14.6K |
2017 Q3
35 quarters
|
|
5943
UBS Asset Management Income Fund, Inc.
CIK
$127M
| $146K | ﹤0.01% |
58,883
+15,452
| +36% | +$39.1K |
2013 Q2
52 quarters
|
|
5944
Quantum eMotion
QNC
$309M
| $146K | ﹤0.01% |
46,780
+29,238
| +167% | +$85K |
2026 Q1
1 quarter
|
|
5945
Belpointe PREP
OZ
$154M
| $145K | ﹤0.01% |
3,212
| – | – |
2022 Q3
15 quarters
|
|
5946
Pebblebrook Hotel Trust 6.375% Series E Preferred Shares
PEB.PRE
$85.8M
| $144K | ﹤0.01% |
7,417
+196
| +3% | +$3.92K |
2025 Q1
5 quarters
|
|
5947
BNY Mellon Dynamic Value ETF
BKDV
$2.13B
| $144K | ﹤0.01% |
+4,300
| New | +$138K |
2026 Q2
0 quarters
|
|
5948
United Bancorp
UBCP
$82.1M
| $143K | ﹤0.01% |
9,031
| – | – |
2015 Q4
42 quarters
|
|
5949
FT Vest US Equity Deep Buffer ETF May
DMAY
$390M
| $143K | ﹤0.01% |
3,043
| – | – |
2024 Q3
7 quarters
|
|
5950
ProShares UltraPro S&P 500
UPRO
$5.66B
| $143K | ﹤0.01% |
1,005
-1
| -0.1% | -$132 |
2016 Q4
38 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.